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A Population-Based Study of Stimulant Drug Treatment
of ADHD and Academic Progress in Children
WHAT’S KNOWN ON THIS SUBJECT: Stimulants are widely used as
a therapeutic option in the United States and increasingly in
Europe. The effect of stimulant drug treatment on academic
performance among children with attention-deﬁcit/hyperactivity
disorder is unclear. Long-term follow-up studies on the topic
are scarce.
WHAT THIS STUDY ADDS: Our results indicate that earlier
stimulant treatment of attention-deﬁcit/hyperactivity disorder is
associated with a lower risk of decline in academic performance.
Girls show a deﬁnite beneﬁt only in mathematics, whereas boys
show marginal beneﬁts in both mathematics and language arts.
abstract
OBJECTIVE: We evaluated the hypothesis that later start of stimulant
treatment of attention-deﬁcit/hyperactivity disorder adversely affects
academic progress in mathematics and language arts among 9- to 12-
year-old children.
METHODS: We linked nationwide data from the Icelandic Medicines Reg-
istry and the Database of National Scholastic Examinations. The study
population comprised 11 872 children born in 1994–1996 who took
standardized tests in both fourth and seventh grade. We estimated
the probability of academic decline (drop of $5.0 percentile points)
according to drug exposure and timing of treatment start between
examinations. To limit confounding by indication, we concentrated on
children who started treatment either early or later, but at some point
between fourth-grade and seventh-grade standardized tests.
RESULTS: In contrast with nonmedicated children, children starting stim-
ulant treatment between their fourth- and seventh-grade tests were more
likely to decline in test performance. The crude probability of academic
decline was 72.9% in mathematics and 42.9% in language arts for
children with a treatment start 25 to 36 months after the fourth-
grade test. Compared with those starting treatment earlier (#12
months after tests), the multivariable adjusted risk ratio (RR) for
decline was 1.7 (95% conﬁdence interval [CI]: 1.2–2.4) in mathematics
and 1.1 (95% CI: 0.7–1.8) in language arts. The adjusted RR of
mathematics decline with later treatment was higher among girls
(RR, 2.7; 95% CI: 1.2–6.0) than boys (RR, 1.4; 95% CI: 0.9–2.0).
CONCLUSIONS: Later start of stimulant drug treatment of attention-
deﬁcit/hyperactivity disorder is associated with academic decline in
mathematics. Pediatrics 2012;130:e53–e62
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Attention-deﬁcit/hyperactivity disorder
(ADHD) is a neurodevelopmental dis-
order affecting 5% to 10% of school-
aged children in the United States
and Europe.1,2 Drug treatment of ADHD
with stimulants (and atomoxetine) is
now widely used as a therapeutic option
in the United States and increasingly in
Europe.1,3–10 Nevertheless, the increasing
use of ADHD drugs is debated, chieﬂy
because of concerns of overuse, addic-
tion, anduncertainty about the long-term
outcomes of treatment.
Stimulant treatment consistently has
been shown to be effective in improving
inattention, hyperactivity, and impulsivity,
the core symptoms of ADHD among
school-aged children,11,12 but evidence
supporting gains in academic perfor-
mance is equivocal.13–15 Controlled trials
have reported acutely improved cogni-
tive performance after short durations
of treatment,16–20 but studies on longer-
term academic effects in naturalistic
settings are scarce. Existing studies, with
follow-up periods from 6 to 13 years,
have revealed improved performance in
mathematics21,22 but inconsistent results
for reading improvement.21,23 Gender-
speciﬁc effects have not been reported;
several methodologic limitations, includ-
ing reliance on self-reports of medica-
tion use, have hindered interpretation.
In Iceland, the use of methylphenidate
stimulants to treat children with ADHD
ismore common than inmost European
countries, ∼5 times the use in the neigh-
boring Nordic countries, and report-
edly similar to use in the United
States.1,24 With∼100%complete national
registration of prescription drug utiliza-
tion and mandatory standardized scho-
lastic tests for all children at age 9 and
12, Iceland offers a unique setting to
study academic performance among
children who are treated with medi-
cation for ADHD.
In this study, we are interested in the
effects of stimulant treatment of ADHD
on academic progress. Comparing all
medicated children with nonmedicated
children would be subject to substantial
bias from confounding by treatment
indication. To limit such bias, we re-
stricted the study to comparisons
among children who were treated but
whose treatment started at different
times. We focused on children starting
treatmentwithin theagerangeof9 to12
years and examined the effect of later
versus early treatment on academic
progress within this group. This restric-
tion leaves a smaller but more homog-
enous study population, reducing the
bias from confounding by indication.
Among children treated either early or
later within the age range of 9 to 12, we
evaluated the hypothesis that a later
start of drug treatment for ADHD would
adversely affect academic progress in
mathematics and language arts.
METHODS
Study Setting and Population
Our source population was all 13 617
children born in 1994, 1995, and 1996
and registered in the Icelandic school
system. We obtained data from January
1, 2003 through December 31, 2008 on
psychotropic drug prescription ﬁlls and
standardized test results in mathemat-
ics and language arts for this national
cohort. By using the personal identiﬁ-
cation number unique to every citizen,
we linked records from the National
Population Registry to the Icelandic
Medicines Registry and the Database of
National Scholastic Examinations. The
ﬁnal study population comprised all
childrenwho took a standardized test in
both fourth grade (age 9) and seventh
grade (age 12) (n = 11 872). Of these
children, 11 619 took both mathematics
examinations, and 11 542 took both
examinations in language arts.
ADHD Drug Exposure
The Icelandic Medicines Registry con-
tains information for each person
dispensed prescription drugs as an
outpatient since January 1, 2003. Com-
pleteness ranges from 93.7% to 99.9% of
alldispensedoutpatientprescriptionsfor
the years 2003–2008. For each dispensed
prescription in the study, we received
information on drug name, number of
deﬁned daily doses (DDDs), Anatomic
Therapeutic Chemical (ATC) code, date,
and pharmacy of the ﬁlled prescription.
ADHD drugs were deﬁned according to
the World Health Organization ATC
classiﬁcation as drugs within the “ner-
vous system” (N) category, pertaining to
the category of “centrally acting sympa-
thomimetics” (N06BA).25 Chemical sub-
stances included were amphetamine
(N06BA01), methylphenidate (N06BA04),
and atomoxetine (N06BA09). Other chem
ical substances within the ATC category
N06BA were not available in Iceland or
not prescribed to children at the time
during the study period. All drugs in-
cluded had ADHD as their main indi-
cation, according to clinical guidelines
and drug package inserts.26,27 The Ice-
landic Medicines Registry does not
hold information on the indication for
drug treatment. In Iceland, however, an
ADHD diagnosis must be veriﬁed by
a pediatric, psychiatric, or neurologic
specialist for reimbursement, so it is
reasonable to assume that essentially
all medicated children fulﬁlled the Dia-
gnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition criteria28
for ADHD before treatment.
We deﬁned the start of therapy to be the
ﬁrst prescription after a period of at
least 11 months during which no pre-
scriptions for an ADHD drug were ﬁlled.
After this period, we considered the
start date of treatment for each child to
be the date of the ﬁrst dispensing of
a prescription for an ADHD drug (stim-
ulant or atomoxetine). To reduce con-
founding by indication, we restricted the
main analysis to children who started
treatment between test dates in fourth
and seventh grade. We categorized me-
dicated children according to the timing
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of their treatment initiation after their
fourth-grade test: within 12 months,
13 to 24 months, or 25 to 36 months
after the fourth-grade test. The last
category we designated as later treat-
ment. The total number of ﬁlled DDDs
corresponds to the cumulative drug
exposure for each child. The DDD is de-
ﬁned by the World Health Organization
Collaborating Centre for Drug Statistics
Methodology. Complete compliance with
this technical unit of measurement (the
equivalent of 30 mg of methylphenidate,
80 mg of atomoxetine, or 15 mg of am-
phetamine per day) would result in the
cumulative DDD for each child being
equal to the number of treatment days
from start to test day. But because chil-
dren might take more or ,1 DDD each
day, the cumulative DDD may not nec-
essarily be equal to the number of
treatment days. We considered treat-
ment to have been discontinued early if
children ﬁlled ,90 DDDs of an ADHD
drug. We classiﬁed children as treated
on their test day in seventh grade if the
number of DDDs on the last prescription
overlapped with the test day.
We assumed that children were being
treated concurrently with other psy-
chotropic drugs if a prescription was
ﬁlled for another psychotropic drug
within the 90-day period after the dis-
pensing of an ADHD drug. Other psy-
chotropic drugs were deﬁned as all
drugs, other than ADHD drugs, pertain-
ing to ATC drug category N, including
antidepressants (N06A), antipsychotics
(N05A), anxiolytics, hypnotics and seda-
tives (N05B, N05C), and other psycho-
tropic drugs (N01, N02, N03, N04, N06C,
N06D, N07).
Academic Outcomes
The standardized tests in mathematics
and language arts are nationally co-
ordinated assessments within the Ice-
landic school system, mandatory for all
children in fourth grade (9-year-olds)
and seventh grade (12-year-olds). We
obtained the test scores, test dates,
school name, and school region for
each child who took tests during 2003–
2008. Some test scores were missing
owing to disability, illness on the test
day, migration to or from Iceland be-
tween tests, or unspeciﬁed absence.
Tests are scored on a scale of 0.0 to 10.0.
We converted the scores to percentiles.
We measured change in performance
by subtracting the fourth-grade per-
centile rank from the seventh-grade
rank. We deﬁned an academic decline
to be a drop of $5.0 percentile points.
Data Analysis
We described medicated and non-
medicated populationsbydemographic
characteristics and by ADHD drug
treatment (ie, type of drugs used, early
discontinuation, concurrent psychotro-
pic drug treatment, and treatment on
test day) according to time of treatment
start. We estimated risks, aswell as risk
ratios(RRs)anddifferences, foradropin
performance in the mathematics and
language arts test. First we estimated
crudemeasures, and thenwe controlled
for performance level on the fourth-
grade test (categorized into terciles),
gender, birth month (categorized as
January–May, June–August, September–
December), birth place (urban, rural,
outside Iceland), school region (urban,
rural), change of schools, concurrent
psychotropic drug treatment, treatment
on test day, and early discontinuation of
ADHD drug treatment (,90 DDDs). For
stratiﬁed analyses, we standardized
results to the distribution of the total
medicated test-participating population
2003–2008.29 In these analyses, we ex-
cluded children who scored in the lowest
ﬁfth percentile on the fourth-grade test,
because they were unable to decline in
rank by at least 5.0 percentile points.
We also conducted a modiﬁed Poisson
regression analysis to adjust for all con-
founders simultaneously.30 Finally, we
ran a sensitivity analysis to assess the
inﬂuence of selection bias that would
result if untested children had a different
association between later treatment
start and academic decline than the
children tested.31 We assumed a range
of reference risks and RRs in the group
of children not taking either or both
examinations. For those who received
early treatment, we assumed values of
25%, 33%, 50%, and 75% for the risk of
academic decline. To each of these as-
sumed values, we then applied a range
of 0% to 100% risk of decline for child-
ren who received later treatment, be-
cause they could have had either a
greater or lesser academic decline than
test-participating children. These as-
sumptions produced a range of RRs
from 0.0 to 4.0 among non–test partic-
ipants with later treatment, which we
then took into account to get an overall
estimate that included projected results
from these missing children.
We used PASW Statistics (version 18;
SPSS Inc, Chicago, IL) and Excel spread-
sheets (Microsoft, Redmond, WA) to
run analyses. This study was approved
by the National Bioethics Committee
(VSNb2008040016/03-7) and the Data
Protection Authority (2008040343) in
Iceland.
RESULTS
Of the 13 617 children registered in the
Icelandic school system, 1029 children
(8%) were treated with ADHD drugs at
any time during the study period. Test
participation, that is, children taking
tests in both fourth and seventh grade
in either mathematics or language arts,
was lower for the total medicated pop-
ulation (72%) than the nonmedicated
general population (88%) (Fig 1). Of 317
children who began treatment between
the fourth- and seventh-grade tests, 236
took both tests, resulting in 65%, 85%,
and 75% participation for children
starting medication at#12 months, 13
to 24 months, and 25 to 36 months, re-
spectively, after the date of fourth-grade
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tests. Demographic and baseline char-
acteristics among test participants
varied only slightly by timing of treat-
ment start (Table 1). Overall, boys were
more likely to be medicated than girls,
aswere children born in the last third of
the calendar year compared with those
born earlier. Medicated children scored
considerably lower on their fourth-grade
tests (taken before their start of treat-
ment) than the nonmedicated population.
Nearly all medicated test-participating
children were treated with methyl-
phenidate (96%); 9% were treated si-
multaneously with the nonstimulant
atomoxetine, and 34% were treated
concurrently with another psychotro-
pic drug (Table 2). Methylphenidate
was used mainly in extended-release
formulations. Of the medicated pop-
ulation, 14% discontinued treatment
within 3 months of initiation; that is,
they ﬁlled ,90 DDDs of an ADHD drug.
Children who started treatment within
12 months after fourth-grade tests re-
ceived, on average, more than double
the supply (ﬁlled DDDs) of ADHD drugs
before tests in seventh grade, com-
pared with those who started later
(Table 2).
Change in Academic Performance
Among children in the nonmedicated
general population, performance on
average did not change much between
tests in fourth and seventh grade; the
crude mean percentile score change
was a rise of 0.4 (95% conﬁdence in-
terval [CI]: 0.0–0.8) in mathematics and
0.0 (95% CI: 20.3 to 0.4) in language
arts. In contrast, mean performance
level among medicated children de-
clined. The decline was concentrated
among those with later treatment ini-
tiation and was much more striking for
mathematics than for language arts,
with a mean decline of 9.4 percentile
points in mathematics for those with
delayed treatment initiation (Table 3).
In mathematics, the risk of a decline of
$5.0 percentile pointswas high among
all medicated students, but especially
high (crude RR: 1.8; 95% CI: 1.3–2.5) for
children who started treatment 25
to 36 months after their fourth-grade
test. The absolute increase in risk
of a decline in mathematics for the
later starters on medication was 32%
FIGURE 1
Origin of study population. a Prevalent users are children already being treated before the fourth-grade
tests. b Incidence users are children who began treatment after the fourth-grade tests.
TABLE 1 Characteristics of Study Population by Exposure to ADHD Drug Treatment
Nonmedicated
Population, n (%)
MedicatedPopulation, TimeSince Fourth-Grade
Test Until ADHD Drug Treatment, n (%)
#12 mo 13–24 mo 25–36 mo
Total 11 126 (100) 85 (100) 90 (100) 61 (100)
Gender
Male 5458 (49) 59 (69) 65 (72) 41 (67)
Female 5668 (51) 26 (31) 25 (28) 20 (33)
Birth year
1994 3751 (34) 36 (42) 34 (38) 17 (28)
1995 3636 (33) 17 (20) 28 (31) 22 (36)
1996 3739 (34) 32 (38) 28 (31) 22 (36)
Birth month
January–April 3682 (33) 23 (27) 26 (29) 18 (30)
May–August 3895(35) 24 (28) 27 (30) 19 (31)
September–December 3459 (32) 38 (45) 37 (41) 24 (39)
Birth place
Urban 6906 (62) 56 (66) 64 (71) 38 (62)
Rural 3522 (32) 24 (28) 22 (24) 19 (31)
Outside Iceland 698 (6) 5 (6) 4 (4) 4 (7)
School region, fourth grade
Urban 6627 (60) 52 (61) 64 (71) 42 (69)
Rural 4499 (40) 33 (39) 26 (29) 19 (31)
Mathematics test, fourth-grade
percentile rank
66.7th–100th 3803 (34) 10 (12) 13 (15) 8 (14)
33.4th–66.6th 3699 (34) 21 (25) 21 (24) 14 (24)
0.1–33.3rd 3512 (32) 52 (63) 55 (62) 36 (62)
Language arts test, fourth-grade
percentile rank
66.7th–100th 3815 (35) 5 (6) 8 (9) 5 (8)
33.4th–66.6th 3706 (34) 23 (27) 17 (19) 20 (33)
0–33.3rd 3459 (31) 57 (67) 63 (72) 35 (58)
Total number of children registered in the Icelandic school system was 13 617, of whom 11 872 (87.2%) took standardized
tests in fourth and seventh grade: 746 of 1029 (72.5%) in the medicated population and 11 126 of 12 588 (88.4%) in the
nonmedicated population.
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(95% CI: 14%–48%). For language arts, in
contrast, the crude RR of academic de-
clinewith later treatmentwas 1.1 (95%CI:
0.7–1.7), and the absolute increase in risk
for academic decline among later start-
ers was only 4% (95% CI:214% to 22%).
Table 4 shows the results for mathe-
matics stratiﬁed singly by children’s
performance level on their fourth-grade
test, gender, and concurrent psycho-
tropic drug treatment. In each strati-
ﬁed display, there is some variation in
the estimates across strata, but in
each case the standardized estimates
were similar to the crude estimates,
indicating little confounding by each
of the stratiﬁcation variables. Later
treatment had a larger effect for chil-
dren who scored in the lowest third
(RR: 2.1) and middle third (RR: 1.9) on
their fourth-grade test than for those
who scored in the highest third (RR:
1.1). The absolute risk of academic
decline in mathematics was higher for
girls than boys (86.7% vs 66.7%), as
was the RR: 3.6 for girls versus 1.4 for
boys. Furthermore, the effect of later
treatment start was slightly stronger
for children not receiving any concur-
rent psychotropic drug treatment than
for those treated concurrently with
other psychotropic drugs. The estimated
effect was increased for children still
being treated with ADHD drugs on their
test day in seventh grade (RR: 1.9) com-
paredwith those no longer being treated
on test day (RR: 1.5).
Table 5 shows the association between
later start of ADHD drug treatment and
decline in language arts performance
stratiﬁed by children’s performance
on their fourth-grade test, gender, and
concurrent psychotropic drug treat-
ment. The adjusted effect estimates did
not differ much from the crude esti-
mates and indicated weak associations.
The estimated effect of later treatment
on decline in language arts was ele-
vated slightly for boys (RR: 1.5), but
showed an inverse association for girls
(RR: 0.6). There was an effect among
those still being treated on test day in
seventh grade (RR: 1.6), but not among
those no longer being treated (RR: 0.8).
The adjusted estimates of the effect
of later drug treatment on academic
performance remained the same
or changed only minimally when we
TABLE 2 Characteristics of ADHD Drug Treatment Among Medicated Children
Time Since Fourth-Grade Test Until ADHD Drug
Treatment
#12 mo 13–24 mo 25–36 mo
Children treated with
Any ADHD drug, n (%) 85 (100) 90 (100) 61 (100)
Methylphenidate, n (%) 84 (99) 87 (97) 55 (90)
Atomoxetine, n (%) 10 (12) 11 (12) 11 (18)
Both, n (%) 9 (11) 8 (9) 5 (8)
Mean age, y (minimum–maximum)
at treatment start
9.8 (9.0–10.7) 10.7 (10.0–11.6) 11.7 (11.0–12.7)
Mean No. (minimum–maximum) of DDDsa
Between fourth- and seventh-grade test 427 (10–1972) 325 (10–1188) 175 (6–594)
Over total study period 662 (10–4302) 547 (10–2250) 361 (20–1278)
Discontinued treatment early (,90 DDDs)
No, n (%) 67 (79) 77 (86) 53 (87)
Yes, n (%) 18 (21) 13 (14) 8 (13)
Treated on test day, seventh grade
Yes, n (%) 34 (40) 35 (39) 41 (67)
No, n (%) 51 (60) 55 (61) 20 (33)
Treated concurrentlyb with
Any psychotropic drug, n (%) 33 (39) 22 (24) 25 (41)
Antidepressants, n (%) 25 (29) 20 (22) 17 (28)
Amitryptiline, n (%) 12 (14) 8 (9) 5 (8)
Antipsychotic, n (%) 12 (14) 7 (8) 12 (20)
Anxiolytic or hypnotic and sedative, n (%) 0 (0) 1 (1) 2 (3)
Other psychotropic drugs, n (%) 4 (5) 5 (6) 3 (4)
a One DDD equals 30 mg of methylphenidate, 80 mg of atomoxetine, or 15 mg of amphetamine.
b Concurrent treatment deﬁned as a ﬁlled prescription for another psychotropic drug within 3 months after a prescription
ﬁlled for an ADHD drug (ATC group N06BA).
TABLE 3 Crude Risks, Risk Differences, and RRs of Academic Decline ($5 Percentile Points)
According to Timing of ADHD Drug Treatment Initiation
Mathematics ADHD Drug Treatment Started, No. of Months
After Fourth- Grade Test
#12 mo 13–24 mo 25–36 mo
Mean percentile score change
(95% CI)
20.3 (24.8 to 4.3) 25.7 (210.5 to 1.0) 29.4 (214.4 to 21.4)
Declined in performance$5.0
percentile points, n
28 36 35
Total, n 68 76 48
Crude risk, % 41 47 73
Risk difference, % (95% CI) 0.0 (ref) 6 (210 to 22) 32 (14 to 48)
RR (95% CI) 1.0 (ref) 1.2 (0.80 to 1.7) 1.8 (1.3 to 2.5)
Language arts
Mean percentile score change
(95% CI)
0.7 (23.4 to 4.8) 21.7 (25.4 to 2.0) 23.4 (29.2 to 2.5)
Declined in performance$5.0
percentile points, n
25 31 21
Total, n 65 72 49
Crude risk, % 39 43 43
Risk difference, % (95% CI) 0.0 (ref) 5 (212 to 21) 4 (214 to 22)
RR (95% CI) 1.0 (ref) 1.1 (0.75 to 1.7) 1.1 (0.71 to 1.7)
ref, reference.
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stratiﬁed the data by other covariates
(ie, birth year, birth month, birth place,
school region, and change of school;
data not shown), indicating only negli-
gible confounding by these variables.
Similarly, the RRs reported in Tables 3
to 5 remained nearly the same when
controlling simultaneously for all cova-
riates in a Poisson regression anal-
ysis: RR = 1.7 (95% CI: 1.2–2.4) in
mathematics and RR = 1.1 (95% CI: 0.7–
1.8) in language arts. Compared with
the nonmedicated general population,
we found that the adjusted risk of ac-
ademic decline was 1.6 times greater
(95% CI: 1.4–1.8) in mathematics and
1.3 times greater (95% CI: 1.1–1.6) in
language arts for children who started
treatment any time between tests in
fourth and seventh grade.
Sensitivity Analysis
Figure 2 displays the estimated RR
from the main analysis adjusted for
hypothetical selection bias (y axis)
given the assumed RRs among non–
test participants (x axis). The depicted
lines, 1 for each assumed reference
risk, represent adjusted RRs for a
range of associations between later
treatment and academic decline among
non–test participant children. These
adjusted RRs varied from 1.0 to 2.2 in
mathematics and from 0.6 to 1.7 in
language arts. The sensitivity analysis
indicates that the basic ﬁndings would
look roughly the same over a broad
range of assumptions about the risks
and associations among children who
did not take both tests.
DISCUSSION
The results of this population-based,
nationwide study indicate that earlier
treatmentwithADHDdrugsbetween the
agesof 9and12years isassociatedwith
a lower risk of a decline in academic
performance, particularly in mathe-
matics. Our data reveal that the ap-
parent advantage of earlier treatment
differs for boys and girls. Girls show
a deﬁnite beneﬁt only in mathematics,
whereas boys show marginal beneﬁts
inbothmathematicsand languagearts.
The study has several important limi-
tations. First, we have no information
about the underlying ADHD diagnosis,
subtype, severity of the condition, or
potential comorbid learning or psychi-
atric disorders. In Iceland, the studied
TABLE 4 Stratiﬁed Risks and Standardized Effect Estimates of Decline in Mathematics According
to Timing of ADHD Drug Treatment Initiation
Time Since Fourth-Grade Test Until ADHD Drug Treatment
#12 mo 13–24 mo 25–36 mo
Performance on fourth-grade test
Scored in lowest third
Declined in performance$5.0
percentile points, n
11 14 16
Total, n 38 42 26
Risk, % 29 33 62
Scored in middle third
Declined in performance$5.0
percentile points, n
9 12 12
Total, n 20 21 14
Risk, % 45 57 86
Scored in highest third
Declined in performance$5.0
percentile points, n
8 10 7
Total, n 10 13 8
Risk, % 80 77 88
Standardized risk, % 42 47 73
Standardized risk difference, %
(95% CI)
0 (ref) 5 (210 to 21) 31 (14 to 47)
Standardized RR (95% CI) 1.0 (ref) 1.1 (0.79 to 1.6) 1.7 (1.3 to 2.4)
Gender
Boys
Declined in performance$5.0
percentile points, n
23 26 22
Total, n 47 55 33
Risk, % 49 47 67
Girls
Declined in performance$5.0
percentile points, n
5 10 13
Total, n 21 21 15
Risk, % 24 48 87
Standardized risk, % 42 47 72
Standardized risk difference, %
(95% CI)
0 (ref) 6 (211 to 22) 31 (13 to 48)
Standardized RR (95% CI) 1.0 (ref) 1.1 (0.79 to 1.6) 1.7 (1.3 to 2.4)
Concurrent psychotropic drug
treatment
No
Declined in performance$5.0
percentile points, n
14 26 18
Total, n 42 57 27
Risk, % 33 46 67
Yes
Declined in performance$5.0
percentile points, n
14 10 17
Total, n 26 19 21
Risk, % 54 53 81
Standardized risk, % 43 49 73
Standardized risk difference, %
(95% CI)
0 (ref) 6 (212 to 24) 30 (13 to 48)
Standardized RR (95% CI) 1.0 (ref) 1.1 (0.77 to 1.7) 1.7 (1.2 to 2.4)
Standardized to the distribution of the total medicated test-participating population, 2003–2008. ref, reference.
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drugs are not reimbursable unless
a diagnosis for ADHD has beenmade by
a specialist. To limit confounding by
indication, we restricted the primary
comparison with children who started
treatment for ADHD sometime between
their tests in fourth and seventh grade,
so that all in the analysis had indica-
tions for ADHD treatment at some point.
Confounding by indication still may
arise from differences that relate to the
age at initiation of treatment. Children
with severe symptoms and more per-
sistent academic problems might be
expected to begin treatment with medi-
cationearlier thanthosewithlesssevere
symptoms. Our results, however, indi-
cate that those who started drug treat-
ment soonest after the fourth-grade
test declined the least academically
in mathematics. The cumulative drug
exposure for these children was, on av-
erage, double the exposure of those
with later treatment. Further, analyses
that included children who started
treatment before the fourth-grade test
andafter theseventh-gradetestresulted
in thesamebasicpatternofresults (data
not shown). We attempted to capture
coexisting psychiatric disorders by ac-
counting for concurrent psychotropic
drug treatment and found that the ob-
served effect of late treatment on aca-
demicperformancewasstrongeramong
those medicated exclusively with stimu-
lants, that is, not concurrently with other
psychotropic drugs. Comorbid learning
disabilities could confound our results if
diagnosed between tests and related to
timing of medication start. The reported
associations could either be exagger-
ated, if such a diagnosis would lead to a
delay in drug treatment start, or under-
estimated, if the diagnosis accelerated
treatment start.
Second, the study lacks information on
concurrent behavioral therapy or edu-
cational school services received by
children in the study population. Avail-
ability of such services in Iceland is low,
however, and in light of evidence indi-
cating that combined therapy provides
onlymodestadvantagescomparedwith
drug treatment alone,12,32 this limita-
tion may not be of major concern.
Third, it is possible that children initi-
ating treatment earlier also have more
family or social support that aids their
academic performance. Because our
ﬁndings are based not on a single test
result but on self-matched comparisons
that contrast seventh-grade test results
with fourth-grade test results, family
setting would not confound the results
TABLE 5 Stratiﬁed Risks and Standardized Effect Estimates of Decline in Language Arts According
to Timing of ADHD Drug Treatment Initiation
Time Since Fourth-Grade Test Until
ADHD Drug Treatment
#12 mo 13–24 mo 25–36 mo
Performance on fourth-grade test
Scored in lowest third
Declined in performance $5.0
percentile points, n
11 16 7
Total, n 38 47 24
Risk, % 29 34 29
Scored in middle third
Declined in performance $5.0
percentile points, n
11 10 10
Total, n 22 17 20
Risk, % 50 59 50
Scored in highest third
Declined in performance $5.0
percentile points, n
3 5 4
Total, n 5 8 5
Risk, % 60 63 80
Standardized risk, % 38 44 41
Standardized risk difference, % (95% CI) 0 (ref) 6 (211 to 22) 3 (216 to 21)
Standardized RR (95% CI) 1.0 (ref) 1.2 (0.77 to 1.7) 1.1 (0.67 to 1.7)
Gender
Boys
Declined in performance $5.0
percentile points, n
14 24 16
Total, n 42 51 31
Risk, % 33 47 52
Girls
Declined in performance $5.0
percentile points, n
11 7 5
Total, n 23 21 18
Risk, % 48 33 28
Standardized risk, % 38 43 45
Standardized risk difference, % (95% CI) 0 (ref) 6 (211 to 22) 7 (211 to 26)
Standardized RR (95% CI) 1.0 (ref) 1.2 (0.76 to 1.7) 1.2 (0.76 to 1.9)
Concurrent psychotropic drug treatment
No
Declined in performance $5.0
percentile points, n
13 23 8
Total, n 38 53 28
Risk, % 34 43 29
Yes
Declined in performance $5.0
percentile points, n
12 8 13
Total, n 27 19 21
Risk, % 44 42 62
Standardized risk, % 39 43 44
Standardized risk difference, % (95% CI) 0 (ref) 4 (214 to 21) 5 (213 to 23)
Standardized RR (95% CI) 1.0 (ref) 1.1 (0.71 to 1.7) 1.1 (0.73 to 1.8)
Standardized to the distribution of the total medicated test-participating population, 2003–2008. ref, reference.
ARTICLE
PEDIATRICS Volume 130, Number 1, July 2012 e59
by guest on June 3, 2016Downloaded from 
unless it had different age-speciﬁc ef-
fects on test performance or the family
dynamic had changed during the time
between the 2 tests. Such effects are
possible. For example, parents could
become increasingly aware of the child’s
problem after the fourth-grade test
results and take additional measures to
improve academic performance.Fourth,
the study would have been stronger if it
included children with ADHD who were
prescribed stimulants but did not actu-
ally take any medication, to account for
the effects of only seeking treatment.
Our study population is limited to ex-
amination takers in both fourth and
seventh grade, and test participation,
as expected, was lower among the medi-
cated population than the nonmedicated
population. Test participation also
varied between early and late treat-
ment initiators between the fourth- and
seventh-grade tests. We assessed this
potential source of bias with a sensitivity
analysis. Assuming a null association
among the non–test participants, we
found that the adjusted main effect esti-
mates did not vary greatly from those
reported among test participants. We
caution that ourmain ﬁndings, however,
may not apply to children too impaired
by ADHD or its comorbidities to partici-
pate in regular school activities.
Consistent with the previously estab-
lished association between ADHD and
poor academic outcomes,22,33–35 we
found that children medicated for
ADHD fare worse academically com-
pared with their nonmedicated peers
and that their performance generally
declines with time, particularly in
mathematics, when initiation of drug
treatment is delayed.
Previous studies lend support to some
of our ﬁndings. Interestingly, Molina
et al22 found that mathematics scores
were the only functional outcome
positively associated with past-year
parent-reported medication use during
follow-up of participants of the Multi-
modal Treatment Study of Children with
ADHDat years 3, 6, and 8 after enrollment,
suggesting a beneﬁcial effect of con-
tinued medication treatment that may
be unique to mathematic achievement.
Studies indicate that language disor-
ders and mathematical disability have
separate cognitive proﬁles.36 Possibly,
stimulant drug treatment has more
positive effects on the cognitive function
underlying mathematical ability than on
that underlying language ability. Schefﬂer
et al21 recently found that parent-reported
drug treatment was associated with
higher mathematic achievement test
scores within a US sample of 594 ele-
mentary school children with ADHD,
but higher reading scores were de-
pendent on longer treatment durations.
Barbaresi et al23 demonstrated that
stimulant treatment of children with
ADHD was associated with improved
reading achievement, decreased school
absenteeism, and decreased grade re-
tention within a population-based sam-
ple of 349 children diagnosedwith ADHD.
The gender difference in our data could
reﬂect random variability from small
numbers, but it alsomightbeconsequent
torealdifferencesintheacademicbeneﬁt
of stimulant treatment. Girls diagnosed
with ADHD present predominantly with
symptoms of inattention and have lower
levels of hyperactivity than boys with
ADHD,37,38 which may play a role in how
early the disorder is detected and when
treatment starts. Previous studies, how-
ever, have found neither gender nor
ADHD subtype as modiﬁers of stimulant
treatment outcomes.20,39,40 The results
of this nationwide follow-up study in-
dicate that early, rather than later, initia-
tion of drug treatment is associated with
a reduced risk of declining academic
performance among boys and girls
with ADHD, especially in mathematics.
Ref. riska
Ref. riska
FIGURE 2
Analysis correcting for possible selection bias, assuming a range of risks of academic decline for non–
test participants. (Mathematics decline is shown in upper panel; language arts decline is shown in
lower panel.) a Ref. risk, risk of academic decline in non–test participants who started treatment early
(#12 months after fourth-grade tests). b RR, academic decline in children who started treatment later
(25–36 months after fourth-grade tests) versus those who started early (#12 months after fourth-
grade tests).
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